ASCO 2026 Preview for China Pharma and Biotech Takeaways from Abstracts

Goldman Sachs previews ASCO 2026 abstracts for China pharma, highlighting significant advancements in NSCLC and SCLC treatments from local companies like Innovent, Kelun, and Zelgen.

Key Takeaways

• 1.The 2026 ASCO abstracts highlight potential disruption in front-line treatments for Non-Small Cell Lung Cancer (NSCLC) by China-developed therapies sac-TMT and ivonescimab.
• 2.Zelgen's alveltamig (ZG006) demonstrated superior survival benefits in 2L+ Small Cell Lung Cancer (SCLC) with a potential median OS of 15-20 months.
• 3.Innovent's IBI363 reached a cORR of 81.8% in combination with chemotherapy for 1L NSCLC, showing competitive efficacy and improved safety at specific dosing.

Table of Contents

• 1L AGA-NSCLC: Continued shaping of new treatments
• SCLC: ZG006 reiterated the long-tail survival of DLL3 TCE in late-line setting
• Late-line NSCLC: Matured survival data brings more visibility on IBI363 in late-line sq-NSCLC
• Positive ph1 data from solid tumor pipelines of BeOne
• Prostate cancer: B7-H3 ADC / AR PROTAC continued shaping up mCRPC landscape
• Gastric cancer: Emerging new CLDN18.2-targeting options for first-line setting

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial